Invion is a life sciences company focussed on the development of treatments for major opportunities in inflammatory diseases. The Group has a number fo drug assets under development or ofr partnering.
Photosoft™ is a new generation photosensitiser derived from chlorophyll which is hypothesised to identify and selectively accumulate within solid cancerous tumour tissues. Photosoft™ is activated at multiple light sensitivity ranges across a broad spectrum, and therefore has potential to be targeted to both surface and deep seated tumours. Invion has an agreement with The Cho Group to conduct clinical development of Photosoft™ globally, leveraging the Company’s expertise. The Cho Group will provide non-dilutive funding to Invion for R&D and clinical trials as part of a global development strategy for the asset. Invion has also been granted exclusivity in Australia and New Zealand to commercialise and distribute Photosoft™ for the treatment of cancers.
INV102 (nadolol) is a beta adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium treat chronic inflammatory airway diseases. A large phase II study in smoking cessation reported successful data in Q4 2015 and feasibility for an inhaled version of the drug is well-progressed with 3M Drug Delivery Systems. A phase II asthma study funded by the US National Institutes of Health is ongoing.
INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. An approved oral therapy, Invion is developing an inhaled version of the drug.
INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis.
Invion is an ASX listed company (ASX:IVX).